Raymedica® Introduces HydraFlex™ Nucleus Arthroplasty System™; Expands Product Portfolio Through the Introduction of Next Generation Technology

MINNEAPOLIS, May 9, 2006— Raymedica®, will introduce it’s next generation technology --- the HydraFlex™ Nucleus Arthroplasty System™ in conjunction with the Spine Arthroplasty Society (SA6) meeting on May 10-13 in Montreal, Canada. Raymedica’s technology will be on display at Booth #321.

With its huge impact on cost, productivity, and general quality of life, the treatment of back pain has attracted a huge investment in time and effort from both industry and academia. The emerging nucleus replacement segment is contained in the U.S. spinal motion preserving and non-fusion products market was worth approximately $186.2 million in 2004. This dynamic market is growing at a compound annual rate of 52% and is projected to reach more than $1.5 billion by 2009.

“This technology is the first of many new developments and introductions that we intend to make over the coming years as we extend our leadership in the nucleus arthroplasty market and set the stage for expansion into additional emerging non-fusion technologies,” commented John J. Viscogliosi, Raymedica’s Chairman and CEO. “We intend to make continuing improvements to our surgical instrumentation and introduce optimized devices for less invasive surgery in the treatment of degenerative disc disease.”

About Raymedica
Raymedica, based in Minneapolis, Minnesota, is the Pioneer in Nucleus Arthroplasty™ having developed the world’s first nucleus replacement device in 1996. Raymedica develops, manufactures and markets medical device systems designed to treat patients with degenerative disc disease that have been unresponsive to non-surgical treatment. Raymedica’s products are currently available in many countries worldwide, but are limited to investigational use only in the United States. For more information, visit the Company's website at http://www.raymedica.com.